Business Description
Beam Therapeutics Inc
NAICS : 325411
SIC : 2833
ISIN : US07373V1052
Description
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.71 | |||||
| Equity-to-Asset | 0.68 | |||||
| Debt-to-Equity | 0.21 | |||||
| Debt-to-EBITDA | -1.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 2.88 | |||||
| Beneish M-Score | 0.48 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 1598 | |||||
| 3-Year EBITDA Growth Rate | 9.5 | |||||
| 3-Year EPS without NRI Growth Rate | 15.7 | |||||
| 3-Year FCF Growth Rate | 0.4 | |||||
| 3-Year Book Growth Rate | 41 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -33.32 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | -41.59 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 62.45 | |||||
| 9-Day RSI | 60.38 | |||||
| 14-Day RSI | 58.58 | |||||
| 3-1 Month Momentum % | 25.83 | |||||
| 6-1 Month Momentum % | 22.08 | |||||
| 12-1 Month Momentum % | 13.88 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.69 | |||||
| Quick Ratio | 5.69 | |||||
| Cash Ratio | 5.57 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12.6 | |||||
| Shareholder Yield % | -0.99 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -52.25 | |||||
| Net Margin % | -41.07 | |||||
| FCF Margin % | -41.58 | |||||
| ROE % | -16.62 | |||||
| ROA % | -10.97 | |||||
| ROIC % | -47.86 | |||||
| 3-Year ROIIC % | -28.81 | |||||
| ROC (Joel Greenblatt) % | -79.43 | |||||
| ROCE % | -16.35 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 6.92 | |||||
| PB Ratio | 3.01 | |||||
| Price-to-Tangible-Book | 3.01 | |||||
| EV-to-EBIT | -9.51 | |||||
| EV-to-Forward-EBIT | -3.76 | |||||
| EV-to-EBITDA | -10.8 | |||||
| EV-to-Forward-EBITDA | -5.02 | |||||
| EV-to-Revenue | 4.97 | |||||
| EV-to-Forward-Revenue | 27.57 | |||||
| EV-to-FCF | -11.95 | |||||
| Price-to-GF-Value | 0.63 | |||||
| Price-to-Net-Current-Asset-Value | 4.22 | |||||
| Price-to-Net-Cash | 4.37 | |||||
| Earnings Yield (Greenblatt) % | -10.52 | |||||
| FCF Yield % | -6.07 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BEAM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Beam Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 349.643 | ||
| EPS (TTM) ($) | -1.76 | ||
| Beta | 2.16 | ||
| 3-Year Sharpe Ratio | -0.16 | ||
| 3-Year Sortino Ratio | -0.26 | ||
| Volatility % | 92.4 | ||
| 14-Day RSI | 58.58 | ||
| 14-Day ATR ($) | 1.946718 | ||
| 20-Day SMA ($) | 26.3045 | ||
| 12-1 Month Momentum % | 13.88 | ||
| 52-Week Range ($) | 20.84 - 49.5 | ||
| Shares Outstanding (Mil) | 82.81 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Beam Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Beam Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Beam Therapeutics Inc Frequently Asked Questions
What is Beam Therapeutics Inc(BEAM)'s stock price today?
The current price of BEAM is $28.90. The 52 week high of BEAM is $49.50 and 52 week low is $20.84.
When is next earnings date of Beam Therapeutics Inc(BEAM)?
The next earnings date of Beam Therapeutics Inc(BEAM) is 2025-02-27 Est..
Does Beam Therapeutics Inc(BEAM) pay dividends? If so, how much?
Beam Therapeutics Inc(BEAM) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers